Ex-Shire exec Phil Vickers joins the migration to startups, taking the reins at an immuno-oncology biotech
A small immuno-oncology company in Toronto has attracted Phil Vickers, a big name in the global R&D scene, to take the reins as the startup’s new CEO.
You might’ve heard of Vickers when he was at Shire, where he led the pharma giant’s global R&D for seven years. When he started there, Vickers oversaw a handful of rare disease programs. By the time he left, he was heading up 40 programs in clinical development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
